Recent Advances in Treating Endometrial and Cervical Cancers - Episode 2

Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

, , , ,

Key opinion leaders review recent updates to the NCCN guidelines for treating recurrent and advanced endometrial cancer, including biomarker testing and targeted therapies like dostarlimab and trastuzumab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Diagnosing and Staging Patients With Endometrial Cancer
    Now Viewing
    EP. 2: Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
    EP. 3: Shared Decision-Making in Advanced or Recurrent Endometrial Cancer
    EP. 4: The Role of dMMR in the Progression of Endometrial Cancer
    EP. 5: Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial
    EP. 6: The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
    EP. 7: Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
    EP. 8: Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
    EP. 9: Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer
    EP. 10: Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
    EP. 11: Staging and Biomarker Testing For Patients With Cervical Cancer
    EP. 12: Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
    EP. 13: Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
    EP. 14: Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
    EP. 15: Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer
    EP. 16: Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
    EP. 17: Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer
    x